SCHEMBL1750784

SCHEMBL1750784

CC(C)(C)OC(=O)N(CCc1ccc(Cl)c(C(C)(C)O[SiH2]C(C)(C)C)c1)C1CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 8/20 0.34
CYP3A4 P08684 1/20 0.32
HTR2A P28223 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
C5AR1 P21730 3/20 0.32
KDM1A O60341 2/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HSD11B1 P28845 1/20 0.31
NR1H4 Q96RI1 1/20 0.31
FGFR4 P22455 1/20 0.31
KCNH2 Q12809 1/20 0.31
GCGR P47871 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1752401 0.91 HTR2A (0.38) RENHTR2AKDM1AHDAC8HDAC6
SCHEMBL3084245 0.85 CDK8 (0.38) MEN1ALDH1A1TP53CYP1A2MAPT
SCHEMBL3087626 0.83 SIGMAR1 (0.34) HTR2AMEN1ALDH1A1TP53CYP1A2
SCHEMBL1751386 0.80 SIGMAR1 (0.33) CYP3A4MEN1ALDH1A1TP53CYP1A2
SCHEMBL1750990 0.79 REN (0.39) RENCYP3A4C5AR1KCNH2
SCHEMBL3095967 0.79 LPAR1 (0.35) MEN1ALDH1A1MAPTKMT2AHDAC6
SCHEMBL3075618 0.79 HTR2C (0.38) MEN1ALDH1A1KMT2A
SCHEMBL1750630 0.79 SMYD2 (0.36) RENSIGMAR1C5AR1KDM1AHDAC8
SCHEMBL3079715 0.77 HDAC3 (0.37) MEN1ALDH1A1MAPTKMT2A
SCHEMBL1751219 0.77 PYCR1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed
EP-1981847-A1 SECONDARY AMINES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2008-10-22 EP disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
WO-2007088514-A1 SECONDARY AMINES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 REN 1/4885CYP3A4 709/4885HTR2A 2555/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 REN 1/4885CYP3A4 676/4885HTR2A 1616/4885
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 REN 1/4885CYP3A4 441/4885HTR2A 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.